Evidence map›Paper›PMID 41911490›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS-STING Pathway.

Liyun Huo, Chong Wu, Xiaobo Li, Caina Ma, Jiamin Huang, Zishuo Chen, Weiling He, Tianyu Tao, Weijing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liyun HuoDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0003-2074-4907
Chong WuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xiaobo LiThe Core Facilities for Medical Science at Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Caina MaDepartment of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Jiamin HuangDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Zishuo ChenDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Weiling HeDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Tianyu TaoCancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0003-1973-5552
Weijing ZhangDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Funding

Fujian Provincial Health and Medical High-Level Talent Team XM050005Guangdong Basic and Applied Basic Research Foundation 2023B111020007Guangdong Basic and Applied Basic Research Foundation 2024B1515040029Guangdong Basic and Applied Basic Research Foundation 2024B1515040030Guangdong Science and Technology Planning Program 2021B1212040017Key Technologies R&D Program of Guangdong Province 2023B1111020005Key Technologies R&D Program of Guangdong Province 2023B1111030003National Key Research And Development Plan 2022YFC3401000National Key Research And Development Plan 2023YFC3402103National Natural Science Foundation of China 82030088National Natural Science Foundation of China 82241231National Natural Science Foundation of China 82403091National Natural Science Foundation of China 82472087National Natural Science Foundation of China 82550006National Natural Science Foundation of China 92359302National Natural Science Foundation of China U24A20740Natural Science Foundation of Fujian Province 2024J011004Shenzhen Medical Research Special Fund C2501003the Funding by Science and Technology Projects in Guangzhou 2024A04J6549
6 · The paper itself

Abstract

The efficacy of immunotherapy in colorectal cancer (CRC) is frequently limited by an immunosuppressive tumor microenvironment. Here, we identify exonuclease/endonuclease/phosphatase domain-containing protein 1 (EEPD1), a gatekeeper of homologous recombination (HR) repair, as a key driver of this immune exclusion. Downregulation of EEPD1 profoundly compromises HR in CRC cells, which curtails their proliferative and metastatic capacities in vitro and in vivo. Mechanistically, EEPD1 deficiency fuels genomic instability, leading to cytosolic DNA accumulation and activation of the cGAS-STING-type I interferon axis. This cascade promotes dendritic cell maturation, skews macrophages toward a proinflammatory M1 phenotype, and enhances tumor-associated antigen presentation, culminating in robust CD8

Indexed as

Colorectal NeoplasmsMembrane ProteinsNucleotidyltransferasesAnimalscGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansImmunotherapyMiceSTING ProteinTumor MicroenvironmentcGAS protein, humancGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseMembrane ProteinsNucleotidyltransferasesSTING Proteinantitumor immunitycGAS‐STING pathwaycolorectal cancerEEPD1immunotherapy

Identifiers

PMID41911490
PMCPMC13285135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.